Replies to post #511008 on Anavex Life Sciences Corp (AVXL)

[baltimorebullet]

From earnings overview:

CEO Christopher Missling reported that Anavex remains “fully committed to bringing oral blarcamesine and oral ANAVEX 3-71 to patients” and will “continue to focus on progressing our clinical trials and regulatory actions.” Missling confirmed the company expects the CHMP to adopt a negative opinion on the MAA for blarcamesine at its December meeting but intends to request a reexamination. He stated, “We intend to request a reexamination of the CHMP opinion upon its formal adoption based on feedback and continued guidance from the CHMP, EMA and the Alzheimer's disease community.”